Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today
Lead investigator Rodney Hicks highlighted the promising retention of MNPR-101-Zr in known disease sites. Monopar plans to present additional data at the European Association of Nuclear Medicine Congress in October 2024 and is set to launch a therapeutic trial with MNPR-101-Lu later this year.Monopar Therapeutics Inc (NASDAQ:MNPR) shares are trading higher by 108% to $4.99 Thursday morning after the company announced early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr's tumor targeting ability in humans.
週四上午，Monopar Therapeutics Inc（納斯達克股票代碼：MNPR）股價上漲108％，至4.99美元，此前該公司公佈了正在進行的開放標籤mnPR-101-ZR 1期成像和劑量測定臨床試驗的早期數據，證實了MnPR-101-ZR對人體的腫瘤靶向能力。
What Happened: Monopar Therapeutics says MNPR-101, a humanized monoclonal antibody targeting uPAR-expressing cancers, demonstrated specific and durable uptake in metastatic tumors on PET scans, compared to standard FDG imaging.
發生了什麼：Monopar Therapeutics表示，與標準的FDG成像相比，針對表達UPAR的癌症的人源化單克隆抗體 MNPR-101 在pET掃描中表現出對轉移性腫瘤的特異性和持久吸收。
Monopar's COO, Andrew Cittadine, expressed satisfaction with the findings, and the company aims to further explore MNPR-101's therapeutic potential in its upcoming Phase 1 trial in Australia.
Monopar的首席運營官安德魯·奇塔丁對研究結果表示滿意，該公司的目標是在即將在澳大利亞進行的1期試驗中進一步探索 MNPR-101 的治療潛力。
Lead investigator Rodney Hicks highlighted the promising retention of MNPR-101-Zr in known disease sites. Monopar plans to present additional data at the European Association of Nuclear Medicine Congress in October 2024 and is set to launch a therapeutic trial with MNPR-101-Lu later this year.
首席研究員羅德尼·希克斯強調了在已知疾病部位保留mnPR-101-ZR的前景。Monopar計劃在2024年10月的歐洲核醫學協會大會上提供更多數據，並定於今年晚些時候啓動一項針對MnPR-101-LU的治療試驗。
Read Also: Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
另請閱讀：精確科學將上漲約33％？以下是分析師對週四的十大預測
How To Buy MNPR Stock
如何購買 MNPR 股票
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了前往經紀平台購買股票的股票（或部分股票）外，您還可以通過購買本身持有股票的交易所交易基金（ETF）來獲得股票，或者將自己分配到401（k）中尋求收購共同基金或其他工具股票的策略。
For example, in Monopar Therapeutics' case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，就Monopar Therapeutics而言，它屬於醫療保健領域。ETF可能會持有許多有助於追蹤該行業的流動性和大型公司的股票，從而使投資者能夠了解該細分市場的趨勢。
According to data from Benzinga Pro, MNPR has a 52-week high of $8.65 and a 52-week low of $1.37.
根據Benzinga Pro的數據，MNPR的52周高點爲8.65美元，52周低點爲1.37美元。
譯文內容由第三人軟體翻譯。
